<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02770404</url>
  </required_header>
  <id_info>
    <org_study_id>W-4873-102 SAD study</org_study_id>
    <nct_id>NCT02770404</nct_id>
  </id_info>
  <brief_title>A Phase 1 Pharmacokinetic Study of Single-Ascending Doses of Intravenous Nafithromycin in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Single-Ascending Doses of Intravenous Nafithromycin in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blind, single-center, placebo-controlled,
      sequential-cohort study in at least 60 healthy adult male and female subjects. Subjects in
      Cohorts 1 through 5 will be randomly assigned in an 8:2 allocation to receive active or
      placebo treatments. Subjects in Cohort 6 will be randomly assigned in a 1:1 allocation to
      receive an IV dose of nafithromycin and a single oral dose of nafithromycin in each crossover
      period. Subjects in each of Cohorts 1, 2, and 3 will receive a single dose of 100, 200, or
      400 mg, respectively, of nafithromycin or matching placebo on Day 1.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2016</start_date>
  <completion_date type="Actual">December 25, 2016</completion_date>
  <primary_completion_date type="Actual">October 25, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve</measure>
    <time_frame>72 hours from dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>72 hours from dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>72 hours from dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical laboratory- Number of subjects with deranged heamatology parameters test results</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead safety ECG results</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reported with any local tolerability at the injection site assessments</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with any abonormal physical examination findings</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of reported AEs</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Nafithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Cohorts 1 through 5 receive active treatments. Subjects in Cohort 6 will receive an IV dose of nafithromycin and a single oral dose of nafithromycin in each crossover period.
Subjects in each of Cohorts 1, 2, and 3 will receive a single dose of 100, 200, or 400 mg, respectively, of nafithromycin on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in Cohorts 1 through 5 will be randomly assigned in an 8:2 allocation to receive active or placebo treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nafithromycin</intervention_name>
    <description>100, 200, or 400 mg of nafithromycin</description>
    <arm_group_label>Nafithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Matching IV placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject between 18 and 55 years of age, both inclusive,

          -  creatinine clearance â‰¥80 mL/minute (Cockcroft-Gault method).

        Exclusion Criteria:

          1. Clinically relevant pathology or any other systemic disorder/major surgeries that in
             the opinion of the investigator would confound the subject's participation and
             follow-up in the clinical study.

          2. Drug or food allergy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Phase 1 unit : Spaulding Clinical Research, LLC</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <last_update_submitted>July 31, 2018</last_update_submitted>
  <last_update_submitted_qc>July 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nafithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

